Charles River Laboratories Intl. Inc vs Innovative Industrial Properties Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Innovative Industrial Properties Inc trades at $51.94 (market cap $1.43B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 10× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Innovative Industrial Properties Inc for 86 Days on average.
| CRL | IIPR | |
|---|---|---|
Market Cap | $14.23B | $1.43B |
Volume | 1,176,885 | 394,222 |
Sector | Health | Real Estate |
52-Week High | $310.77 | $64.67 |
52-Week Low | $149.93 | $44.58 |
Typical Hold Time | 33 Days | 86 Days |
Enterprise Value | $17.06B | $1.96B |
Dividend Yield | — | 14.64% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
IIPR trades at $51.83, up 1.17% on the day, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 11.75 and P/B of 0.83, but revenue declined to $265.96M in 2025. Recent news highlights a $245 million mezzanine loan commitment and a quarterly dividend of $1.90, underscoring its REIT structure and focus on cannabis real estate.
The outlook is cautious due to tenant defaults and dividend sustainability concerns, though the stock offers a high yield and potential regulatory catalysts. Risks include sector volatility and financial performance pressures, while analyst consensus leans hold with a $84.67 price target suggesting upside if operational stability improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →